Amgen Q2 FY26 GAAP EPS rises 65% to $4.37; revenue increases 10% to $10.1 billion - AMGN News | RalliesAmgen Q2 FY26 GAAP EPS rises 65% to $4.37; revenue increases 10% to $10.1 billion
A
AMGN• Product sales and guidance
- Repatha sales rose 37% to $953 million; Prolia sales fell 32% to $759 million as multiple biosimilars launched globally.
- 2026 guidance: revenue $38.2 billion-$39.4 billion; GAAP EPS $15.80-$17.08; non-GAAP EPS $22.30-$23.50.
Q2 FY26 results and margin expansion
- Amgen Q2 2026 revenue rose 10% to $10.1 billion; GAAP diluted EPS jumped 65% to $4.37.
- GAAP operating income climbed to $3.5 billion; operating margin widened 6.5 percentage points to 36.8%.
- Free cash flow increased to $3.5 billion from $1.9 billion, reflecting the final repatriation tax payment in Q2 2025.
PARR
•
